Impact of polyethylene glycol 400/propylene glycol/hydroxypropyl-guar and 0.1% sodium hyaluronate on postoperative discomfort following cataract extraction surgery: a comparative study
© The Author(s). 2017
Received: 17 January 2017
Accepted: 1 May 2017
Published: 10 May 2017
Universal postoperative guidelines for cataract extraction surgery are yet to be introduced. Artificial tears are gaining popularity as an additional integral component of the postoperative regime. The primary objective of this study was to explore the impact of two prevalent artificial tear preparations on postoperative discomfort following cataract extraction surgery.
A total of 180 patients that underwent cataract extraction surgery were randomly divided into three groups according to their postoperative regime: a) Study group 1 (SG1) received a fixed combination of tobramycin and dexamethasone (FCTD) quid for 3 weeks and, additionally polyethylene glycol 400/propylene glycol/hydroxypropyl-guar quid, for 6 weeks, b) Study group 2 (SG2) received FCTD quid for 3 weeks and, additionally 0.1% sodium hyaluronate provided in the COMOD® device quid, for 6 weeks, and, c) Control Group (CG) received only FCTD quid for 3 weeks. The following indexes were evaluated at three postoperative checkpoints: 1) Subjective discomfort index (SDI) derived from four direct 10-scale Likert-type questions that were addressed to the patient and pertained to: a) foreign body sensation (FBS), b) blinking discomfort (BD), c) stinging sensation (SS), d) tearing sensation (TS), 2) Tear break-up time (TBUT), 3) Central corneal thickness (CCT) and, 4) Central Corneal Sensitivity (CCS).
Both groups showed increased CCT values at the first examination point and reduced CCS values at all examination points. Furthermore, both SGs had better TBUT times at all examination points compared to CG (CG: 8.86 ± 1.08, SG1: 9.59 ± 1.45, CG2: 9.45 ± 1.33, p < 0.05). BD was significantly better in both SGs only at the 1st week of examination, while SDI values were better until the 3rd week and only borderline better at 6th week. Lastly, no significant differences were detected between SGs, regarding all parameters, at all examination points.
Polyethylene glycol 400/propylene glycol/hydroxypropyl-guar and 0.1% sodium hyaluronate provided in the COMOD® device seem to be equally efficient in alleviating OSD symptoms following cataract extraction surgery and any of them should be routinely added to the postoperative regime.
ClinicalTrials.gov Identifier: https://clinicaltrials.gov/ct2/show/NCT02558218NCT02558218
KeywordsCataract Postoperative regimen Artificial tears Surface discomfort index Systane Hylocomod
Cataract is a condition that affects a large number of the middle aged population, being responsible for 33% of visual impairment worldwide and nearly 51% of blindness . The treatment of choice is phacofragmentation, either with ultrasound, liquefaction or laser-assisted; and implantation of an artificial monofocal or multifocal lens inside the capsular bag [2–5]. Cataract extraction surgery is a minimally invasive technique that, in the majority of the cases, is done as an outpatient’s service. Moreover, it is considered to have a short and uneventful recovery period. However, published literature revealed only a few studies concerning postoperative irritation symptoms and pain among cataract patients. Furthermore, the results varied, referring to either decreased or increased percentages of patients experiencing adverse effects after phacoemulsification [6, 7].
In fact, the postoperative regime of patients that underwent cataract extraction aims primarily in preventing endophthalmitis, persistent corneal edema and cystoid macular edema [8, 9]. However, apart from these complications, a series of non-vision-threatening adverse events have been identified that cause great discomfort and frustration to the patient, like pain, foreign body sensation, and itchiness. These symptoms are considered to be associated with postoperative inflammation, corneal nerve transection and overall instability of the corneal tear film [10, 11].
Although universal postoperative guidelines for cataract extraction surgery are yet to be introduced, common practices can easily be identified. Most cataract surgeons prefer fixed combinations of antibiotic with corticosteroids for at least three weeks following cataract extraction. In hard nuclei, when intense energy is delivered in the eye, non-steroidal anti-inflammatory drugs (NSAIDs) can be administered as well. Unfortunately, both aforementioned fixed combinations and NSAIDs do not prevent the temporary symptoms of ocular surface disease (OSD) that almost all cataract patients experience. Therefore, artificial tears are gaining popularity as an additional integral component of the postoperative regime in order to alleviate OSD-related symptomatology.
Among the popular artificial tears medications are the: a) polyethylene glycol 400/propylene glycol/hydroxypropyl-guar (Systane Ultra, Alcon, Greece) consisting of Polyethylene Glycol 400 0.4% and Propylene Glycol 0.3% and b) 0.1% sodium hyaluronate provided in the continuous monodose system COMOD® (Hylocomod, Farmex, Greece). COMOD device is an integral airless application system, which enables delivery of multiple sterile doses of a liquid medicinal product. Both medications are considered to be highly effective in dry-eye-disease (DED) and prospectively in moderate and severe OSD. However, both medications have not been comparatively evaluated for their potential beneficial impact on cataract patients.
Within this context, the present study objective was to explore the impact of two contemporary artificial tear preparations on postoperative discomfort following cataract extraction surgery.
This was a prospective, clinic-based, randomized trial. Study protocol adhered to the tenets of the Helsinki Declaration and written informed consent was obtained from all participants. The Institutional Review Board of the Democritus University of Thrace approved the protocol and the study was conducted at the University Hospital of Alexandroupolis (UHA), Greece, between September and December 2015. Official registration number of the study is: NCT02558218
Participants were recruited from the Cataract Service of the UHA in a consecutive-if-eligible basis. Eligibility criteria included diagnosis of senile cataract. Exclusion criteria for all study groups included: diagnosis or evidence of dry-eye-disease (DED), IOP-lowering medications, former incisional surgery, former diagnosis of corneal disease, diabetes, autoimmune or mental diseases. By means of a custom computer randomization program, all participants were randomly assigned to three study groups according to the postoperative regime that was prescribed: a) Study group 1 (SG1) received a fixed combination of tobramycin and dexamethasone (FCTD), (Tobradex, Alcon, Greece) quid for 3 weeks and, additionally Systane Ultra, Alcon, Greece quid, for 6 weeks, b) Study group 2 (SG2) received Tobradex quid for 3 weeks and, additionally Hylocomod quid, for 6 weeks, and, c) Control Group (CG) received only Tobradex quid for 3 weeks.
All operations were performed by the same surgeon (G.L.) in a consistent way using the Alcon Infiniti VisionSystem platform (80% continuous amplitude with 350mmHg vacuum limit and 40ml/min aspiration flow rate), as described previously . In brief, by means of a 2.2mm, superior-temporal or superior-nasal (eleven o’clock), self-sealing, clear-cornea incision, 3% Sodium Hyaluronate and 4% Chondroitin Sulfate (Viscoat, Alcon, Greece) were injected for the phacofragmentation phase and 1% Sodium Hyaluronate (Provisc, Alcon, Greece) for the rest of the intraocular lens implantation phase . For all participants, the foldable hydrophilic acrylic intraocular lens SN60WF (Alcon) was inserted in the capsular bag.
The following parameters were comparatively evaluated 1, 3 and 6 weeks postoperatively: 1) Subjective discomfort index (SDI) was derived using four direct 10-scale Likert-type questions (Additional file 1) that were addressed to the patient and pertained to: a) foreign body sensation (FBS), b) blinking discomfort (BD), c) stinging sensation (SS), d) tearing sensation (TS), 2) Tear break-up time (TBUT), 3) Central corneal thickness (CCT) using anterior segment optical coherence tomography and, 4) Central Corneal Sensitivity (CCS) using the Cochet-Bonnet aesthesiometer.
Validation of the subjective discomfort index
Validation of the SDI was performed in a sample of 40 participants who visited our cornea outpatient service for dry eye disease (DED). These participants populated four validation groups according to their DED severity, as suggested by the Dysfunctional Tear Study group [13, 14]. Construct validity was assessed with one-way analysis of variance (ANOVA) in order to confirm that all indexes could efficiently discriminate validation groups based on their DED progress. All indexes presented significant discriminant ability (p < 0.05). Moreover, test-retest reliability was assessed for the four validation groups by calculation of intraclass correlation coefficients (ICCs) for all indexes at two different visits with an average time-window of 1 month, to prevent memory effect. All ICCs were above 0.90 indicating excellent reliability of the indexes.
An a priori power analysis was performed. For an effect size of 0.74, 52 participants would be required in each group, for the study to have a power of 0.8 at the significance level of 0.05. The normality of measured data was evaluated by Kolmogorov-Smirnov test. Normal distribution data were assessed by Student’s t-test. Non-parametric data were assessed with Mann–Whitney U test. Multiple comparisons among the three groups were assessed by analysis of variance (ANOVA). Values at the p < 0.05 were considered statistically significant. All statistical analyses were performed with the Medcalc version 188.8.131.52 (Medcalc Software, Mariakerke, Belgium).
Preoperative data for all participants
Group comparisons preoperatively
529 ± 21
532 ± 28
539 ± 24
5.45 ± 0.72
5.39 ± 0.58
5.41 ± 0.73
9.21 ± 0.99
8.94 ± 1.11
9.01 ± 1.05
Group comparisons on the 1st week
550 ± 36♭
560 ± 28♭
564 ± 41♭
4.41 ± 0.92♭
4.31 ± 1.89♭
4.24 ± 1.55♭
8.62 ± 1.45♭
9.35 ± 1.34♭
9.38 ± 1.11♭
7.74 ± 1.41
8.92 ± 1.39
8.99 ± 1.45
8.85 ± 1.98
9.24 ± 0.56
9.31 ± 0.62
9.08 ± 1.67
9.11 ± 1.21
9.02 ± 0.87
8.99 ± 1.22
9.05 ± 0.88
9.01 ± 0.91
8.66 ± 1.57
9.08 ± 1.01
9.15 ± 1.16
Group comparisons on the 3rd week
541 ± 32
549 ± 38
555 ± 52
4.75 ± 1.14♭
4.69 ± 1.26♭
4.72 ± 1.41♭
8.98 ± 1.52♭
9.41 ± 1.28♭
9.47 ± 1.13♭
7.92 ± 2.15
9.21 ± 1.89
9.12 ± 1.73
9.05 ± 1.43
9.19 ± 0.74
9.22 ± 0.97
9.12 ± 1.47
9.05 ± 0.91
9.09 ± 1.04
9.11 ± 0.78
9.06 ± 0.77
9.15 ± 0.94
8.80 ± 1.46
9.12 ± 1.76
9.07 ± 1.52
Group comparisons on the 6th week
548 ± 29
550 ± 25
543 ± 31
4.82 ± 0.87♭
4.77 ± 1.31♭
4.79 ± 1.26♭
8.86 ± 1.08♭
9.59 ± 1.45♭
9.45 ± 1.33♭
8.08 ± 1.23
9.19 ± 1.65
9.21 ± 1.42
9.11 ± 0.97
9.21 ± 0.36
9.14 ± 0.47
9.02 ± 1.15
9.09 ± 0.64
9.11 ± 0.73
9.08 ± 0.85
9.06 ± 0.59
9.13 ± 0.87
8.82 ± 1.05
9.13 ± 0.81
9.17 ± 0.58
Cataract extraction is considered the most prevalent ophthalmological operation both in the developing and the developed societies [15, 16]. Despite the advances in cataract-extraction techniques and cataract-related technology, a series of intraoperative and postoperative adverse-effects and complications have been associated with this prevalent surgical modality. Among the mild ones are the transient corneal edema and the reduced corneal sensitivity. More severe ones include the permanent corneal decompensation due to endothelial cell damage. However, in the majority of published trials, cataract extraction surgery seems to provide excellent visual outcomes  with high levels of patient satisfaction . In fact, the postoperative visual rehabilitation results in an average 2.8 quality-adjusted-life-years (QUALYs) for bilateral cases. Despite this impressive outcome, it is common knowledge that cataract patients do experience dry-eye symptoms of variable severity and variable duration in the postoperative period . Within this context, the present study attempted to explore the beneficial impact of two prevalent artificial tears preparations in preventing or effectively managing dry-eye symptoms.
In order to explore the potential efficacy of each, we reviewed the literature to identify the most common DED symptoms that cataract patients experience following extraction surgery. The most common symptoms from the literature [20–23] were: foreign body sensation, blinking discomfort, stinging sensation, and tearing sensation. These four common DED-related disturbances allowed us to construct an overall discomfort index (the Surface Discomfort Index) that quantified the overall perceived discomfort that the patients experienced. Prior to addressing the questionnaires to the patients, we attempted a validation pre-study, which suggested excellent construct validity and reliability of the index.
Both artificial tears used, Systane Ultra [24, 25] and Hylocomod  , are considered highly effective in ocular surface disorders. Systane Ultra, which combines polyethylene glycol 400, propylene glycol and hydroxypropyl-guar, acts through a unique biphasic mechanism of action, in which the product first binds to damaged hydrophobic areas of epithelial cells to add volume to the tear film and then restructures the tear film by forming a protective gel matrix that provides long-lasting protection . Hylocomod contains 0.1% sodium hyaluronate, which mimics the rheological properties of the aqueous layer, hence produces a beneficial effect to the ocular surface by stabilizing it .
Our study outcomes indicated significant improvement of the TBUT index for both study groups. TBUT improvement was associated with significant improvement of the SDI index; the latter finding was primarily attributed to the significant reduction of the foreign body sensation for the whole postoperative period and the significant reduction of the blinking discomfort for the first postoperative week. On the other hand, both study groups demonstrated better results, albeit not significant, for the stinging sensation and the tearing sensation when compared to the control group that received only the standard postoperative regime. Moreover, none of the study groups presented significant superiority over the other, for all postoperative examination points. It seems that the biphasic protective mechanism of Systane Ultra provides no additional beneficial impact over the monophasic Hylocomod, at least for the early postoperative period.
Our results are in accordance to former published studies that reported significant improvement of TBUT and foreign body sensation when 0.1% sodium hyaluronate and 0.5% carboxymethylcellulose ophthalmic solution was additionally prescribed for the postoperative regime . In fact, the effective postoperative management of the ocular surface that the additional artificial tears medication provides, improves patient satisfaction significantly with the surgical outcome and fosters the bond between the physician and the patient [30, 31].
Taking into account the limitations of this study i.e., the short duration of the postoperative assessment and its single-centered design, our statistically robust number of patients suggests that both Systane ultra and Hylocomod are equally efficient in alleviating OSD symptoms following cataract extraction surgery and should be routinely added to the postoperative regime.
GL designed the study and wrote the manuscript. PN collected data and assisted in manuscript writing. HS performed all statistical analysis. VK supervised the study. All authors read and approved the final manuscript.
The authors declare that they have no competing interests. None of the authors have received reimbursements, fees, funding, or salary in the past 5 years from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future. None of the authors hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future. None of the authors have received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript. None of the authors of this manuscript have a financial interest in any material or method related to this work. No conflicting relationship exists for the authors.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol. 2012;96(5):614–8.View ArticlePubMedGoogle Scholar
- Labiris G, Toli A, Polychroni D, Gkika M, Angelonias D, Kozobolis VP. Liquefaction for cataract extraction. Int J Ophthalmol. 2016;9(2):306–11.PubMedPubMed CentralGoogle Scholar
- Labiris G, Gatzioufas Z, Giarmoukakis A, Sideroudi H, Kozobolis VP. Liquefaction versus torsional IP: a comparative study on endothelial cells, corneal edema and corneal sensitivity. Ophthalmic Res. 2013;49(1):37–42.View ArticlePubMedGoogle Scholar
- Day AC, Gore DM, Bunce C, Evans JR. Laser-assisted cataract surgery versus standard ultrasound phacoemulsification cataract surgery. Cochrane Database Syst Rev. 2016;7:CD010735. doi: 10.1002/14651858.CD010735.pub2.
- Labiris G, Giarmoukakis A, Patsiamanidi M, Papadopoulos Z, Kozobolis VP. Mini-monovision versus multifocal intraocular lens implantation. J Cataract Refract Surg. 2015;41(1):53–7.View ArticlePubMedGoogle Scholar
- Sutu C, Fukuoka H, Afshari NA. Mechanisms and management of dry eye in cataract surgery patients. Curr Opin Ophthalmol. 2016;27(1):24–30.View ArticlePubMedGoogle Scholar
- Kasetsuwan N, Satitpitakul V, Changul T, Jariyakosol S. Incidence and pattern of dry eye after cataract surgery. PLoS ONE. 2013;8(11):e78657.View ArticlePubMedPubMed CentralGoogle Scholar
- Kim SJ, Schoenberger SD, Thorne JE, Ehlers JP, Yeh S, Bakri SJ. Topical Nonsteroidal Anti-inflammatory Drugs and Cataract Surgery: A Report by the American Academy of Ophthalmology. Ophthalmology. 2015;122(11):2159–68.View ArticlePubMedGoogle Scholar
- Behndig A, Cochener B, Güell JL, Kodjikian L, Mencucci R, Nuijts RM, et al. Endophthalmitis prophylaxis in cataract surgery: overview of current practice patterns in 9 European countries. J Cataract Refract Surg. 2013;39(9):1421–31.View ArticlePubMedGoogle Scholar
- Sitompul R, Sancoyo GS, Hutauruk JA, Gondhowiardjo TD. Sensitivity change in cornea and tear layer due to incision difference on cataract surgery with either manual small-incision cataract surgery or phacoemulsification. Cornea. 2008;27 Suppl 1:S13–8.View ArticlePubMedGoogle Scholar
- Jiang D, Xiao X, Fu T, Mashaghi A, Liu Q, Hong J. Transient Tear Film Dysfunction after Cataract Surgery in Diabetic Patients. PLoS ONE. 2016;11(1):e0146752. doi: 10.1371/journal.pone.0146752.
- Labiris G, Sideroudi H, Rousopoulos K, Kozobolis VP. Cohesive versus dispersive-cohesive ophthalmic viscosurgical device in torsional intelligent phaco. J Cataract Refract Surg. 2015;41(3):681–2.View ArticlePubMedGoogle Scholar
- Behrens A, Doyle JJ, Stern L, Chuck RS, McDonnell PJ, Azar DT, et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea. 2006;25(8):900–7.View ArticlePubMedGoogle Scholar
- Milner MS, Beckman KA, Luchs JI, Allen QB, Awdeh RM, Berdahl J, et al. Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment. Curr Opin Ophthalmol. 2017;27 Suppl 1:3–47.View ArticlePubMedGoogle Scholar
- Liu Y, Zeng M, Liu X, Luo L, Yuan Z, Xia Y, et al. Torsional mode versus conventional ultrasound mode phacoemulsification. Randomized comparative clinical study. J Cataract Refract Surg. 2007;33:287–92.View ArticlePubMedGoogle Scholar
- Williams A, Sloan FA, Lee PP. Longitudinal rates of cataract surgery. Arch Ophthalmol. 2006;124:1308–14.View ArticlePubMedGoogle Scholar
- Hood CT, Sugar A. Subjective complaints after cataract surgery: common causes and management strategies. Curr Opin Ophthalmol. 2015;26(1):45–9.View ArticlePubMedGoogle Scholar
- Brown GC, Brown MM, Menezes A, Busbee BG, Lieske HB, Lieske PA. Cataract surgery cost utility revisited in 2012: a new economic paradigm. Ophthalmology. 2013;120:2367–76.View ArticlePubMedGoogle Scholar
- Li XM, Hu L, Hu J, Wang W. Investigation of dry eye disease and analysis of the pathogenic factors in patients after cataract surgery. Cornea. 2007;26(9 suppl 1):S16–20.View ArticlePubMedGoogle Scholar
- Silverstein SM, Cable MG, Sadri E, Peace JH, Fong R, Chandler SP, et al. Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain. Curr Med Res Opin. 2011;27(9):1693–703.View ArticlePubMedGoogle Scholar
- Maxwell WA, Reiser HJ, Stewart RH, Cavanagh HD, Walters TR, Sager DP, et al. Nepafenac dosing frequency for ocular pain and inflammation associated with cataract surgery. J Ocul Pharmacol Ther. 2008;24(6):593–9.View ArticlePubMedGoogle Scholar
- Camesasca FI, Bianchi C, Beltrame G, Caporossi A, Piovella M, Rapisarda A, et al. Control of inflammation and prophylaxis of endophthalmitis after cataract surgery: A multicenter study. Eur J Ophthalmol. 2007;17(1):733–42.Google Scholar
- Fong R, Leitritz M, Siou-Mermet R, Erb T. Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial. Clin Ophthalmol. 2012;6:1113–24.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang Y, Cao H, Lin T, Gong L. Effects of artificial tears on rabbit ocular surface healing after exposure to benzalkonium chloride. Drug Chem Toxicol. 2016;39(4):455–60.View ArticlePubMedGoogle Scholar
- Benelli U. Systane lubricant eye drops in the management of ocular dryness. Clin Ophthalmol. 2011;5:783–90.View ArticlePubMedPubMed CentralGoogle Scholar
- Schrage N, Frentz M, Spoeler F. The Ex Vivo Eye Irritation Test (EVEIT) in evaluation of artificial tears: Purite-preserved versus unpreserved eye drops. Graefes Arch Clin Exp Ophthalmol. 2012;250(9):1333–40.View ArticlePubMedGoogle Scholar
- Christensen MT, Cohen S, Rinehart J, Akers F, Pemberton B, Bloomenstein M, et al. Clinical evaluation of an HP-guar gellable lubricant eye drop for the relief of dryness of the eye. Curr Eye Res. 2004;28(1):55–62.View ArticlePubMedGoogle Scholar
- Guillon M, Maissa C, Ho S. Evaluation of the effects on conjunctival tissues of Optive eyedrops over one month usage. Cont Lens Anterior Eye. 2010;33(2):93–9.View ArticlePubMedGoogle Scholar
- Mencucci R, Boccalini C, Caputo R, Favuzza E. Effect of a hyaluronic acid and carboxymethylcellulose ophthalmic solution on ocular comfort and tear-film instability after cataract surgery. J Cataract Refract Surg. 2015;41(8):1699–704.View ArticlePubMedGoogle Scholar
- Hardten DR. Dry eye disease in patients after cataract surgery. Cornea. 2008;27(7):855.View ArticlePubMedGoogle Scholar
- Sánchez MA, Arriola-Villalobos P, Torralbo-Jiménez P, Girón N, de la Heras B, Herrero Vanrell R, et al. The effect of preservative-free HP-Guar on dry eye after phacoemulsification: a flow cytometric study. Eye (Lond). 2010;24(8):1331–7.View ArticleGoogle Scholar